Genetic associations of prolactin increase in olanzapine/fluoxetine
combination-treated patients.
Author(s): Houston JP, Fijal B, Heinloth AN, Adams DH.
Affiliation(s): Lilly USA, LLC, Indianapolis, IN 46285, USA. houston_john_p@lilly.com
Publication date & source: 2010, Psychiatry Res. , 175(1-2):171-2
In patients from two clinical trials, we investigated the associations of single
nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes
during treatment with olanzapine/fluoxetine combination. In both cohorts, three
dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may
influence susceptibility to hyperprolactinemia associated with antipsychotic
treatment.
|